Literature DB >> 11289283

Rectal cancer: local recurrence after surgery without radiotherapy.

F A Bonadeo1, C A Vaccaro, M L Benati, G M Quintana, X E Garione, M T Telenta.   

Abstract

PURPOSE: This study was designed to assess the local recurrence rate and prognostic factors for local recurrence in patients undergoing curative anterior or abdominoperineal resections without radiotherapy.
METHODS: From January 1980 to December 1996, 514 consecutive patients underwent curative resections for rectal cancer. We excluded those with preoperative radiotherapy (n = 23), postoperative radiotherapy (n = 27), local resection (n = 36), and 11 (2.1 percent) patients who died postoperatively. The remaining 417 patients (249 males) with a median age of 64 (range, 21-90) years were analyzed. For upper third lesions, mesorectal tissue was excised down to at least 5 cm below the tumor. Total mesorectal excision was performed for lower and middle tumors. Postoperative chemotherapy was limited to patients with Stage III lesions. Median follow-up (and 95 percent confidence interval) was (5.2 4.3-5.9) years, with 87.7 percent of patients followed up longer than 24 months. Local recurrence was defined as any recurrence within the field of resection, regardless of the presence or absence of distant metastasis.
RESULTS: Five-year local recurrence rate(and 95 percent confidence interval) was 9.7 (6.4-13) percent, with a median time to diagnosis of 15 (10-23) months. Local recurrence rates in Stages I, II, and III were: 3.1, 4.1, and 24.1 percent, respectively (P < 0.0001). In relation to node status, local recurrence rates were N0, 4.1 (1.7-6.5) percent; N1, 12.6 (4.6-20.6) percent; N2, 32.1 (12.1-52.1) percent; and N3, 59.3 (22.5-96.1) percent; (P < 0.00001). Lower third tumors had a higher local recurrence rate than middle and upper third tumors: 17.9, 7.1, and 5.1 percent, respectively (P = 0.002). Adjusted by stage, this difference was maintained only in Stage III tumors. Among lower tumors, those at 6 and 7 cm from the anal verge had a lower local recurrence rate than those below 6 cm (6.7 vs. 26.2 percent, respectively; P = 0.02). Accidental rectal perforation at or near the tumor site occurred in 12 cases (2.9 percent), showing a strong correlation with local recurrence (P < 0.0001). Multivariate analysis showed significant higher risk for lower third tumors (hazard ratio, 2.98) and positive nodes (hazard ratio, 4.78).
CONCLUSIONS: Appropriate surgery without irradiation achieves excellent local control in N0 rectal cancers. Node metastasis, lower third localization (especially below 6 cm), and accidental rectal perforation at or near the tumor site are significantly associated with a higher local recurrence rate.

Entities:  

Mesh:

Year:  2001        PMID: 11289283     DOI: 10.1007/bf02234736

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  16 in total

1.  Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial?

Authors:  Jin Soo Kim; Nam Kyu Kim; Byung Soh Min; Hyuk Hur; Joong Bae Ahn; Ki Chang Keum
Journal:  Int J Colorectal Dis       Date:  2010-06-11       Impact factor: 2.571

2.  Identification and Quantification of Drug-Resistant Cells in Colorectal Tumor and Distal Margin.

Authors:  K Chandramohan; Tapas Pradhan; S Asha Nair
Journal:  Indian J Surg Oncol       Date:  2017-02-11

3.  Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Fábio G Campos; Wladimir Nadalin; Desiderio Kiss; Joaquim Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

4.  Differences in tissue degeneration between preoperative chemotherapy and preoperative chemoradiotherapy for colorectal cancer.

Authors:  Yuji Nishizawa; Satoshi Fujii; Norio Saito; Masaaki Ito; Kentaro Nakajima; Atsushi Ochiai; Masanori Sugito; Akihiro Kobayashi; Yusuke Nishizawa
Journal:  Int J Colorectal Dis       Date:  2012-02-29       Impact factor: 2.571

5.  Factors affecting management decisions in rectal cancer in clinical practice: results from a national survey.

Authors:  A Habr-Gama; R O Perez; G P São Julião; I Proscurshim; S C Nahas; J Gama-Rodrigues
Journal:  Tech Coloproctol       Date:  2010-11-06       Impact factor: 3.781

6.  Clinically Node Negative, Pathologically Node Positive Rectal Cancer Patients Who Did Not Receive Neoadjuvant Therapy.

Authors:  Nouf Akeel; Nan Lan; Luca Stocchi; Meagan M Costedio; David W Dietz; Emre Gorgun; Matthew F Kalady; Georgios Karagkounis; Hermann Kessler; Feza H Remzi
Journal:  J Gastrointest Surg       Date:  2016-10-27       Impact factor: 3.452

7.  Local recurrence after laparoscopic resection of T3 rectal cancer without preoperative chemoradiation and a risk group analysis: an Asian collaborative study.

Authors:  Sun-Il Lee; Seon-Hahn Kim; Hwei-Ming Wang; Gyu-Seog Choi; Min-Hua Zheng; Masaki Fukunaga; Jun-Gi Kim; Wai Lun Law; Joe-Bin Chen
Journal:  J Gastrointest Surg       Date:  2007-10-24       Impact factor: 3.452

8.  Association between pathologic features of peripheral nerves and postoperative anal function after neoadjuvant therapy for low rectal cancer.

Authors:  Keinchi Koushi; Yuji Nishizawa; Motohiro Kojima; Satoshi Fujii; Norio Saito; Ryuichi Hayashi; Atsushi Ochiai; Masaaki Ito
Journal:  Int J Colorectal Dis       Date:  2016-09-21       Impact factor: 2.571

9.  Abdominoperineal excision following preoperative radiotherapy for rectal cancer: unfavorable prognosis even with negative circumferential resection margin.

Authors:  Lin Wang; Guo-Li Gu; Zhong-Wu Li; Yi-Fan Peng; Jin Gu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

10.  Evaluation of lateral lymph node dissection with preoperative chemo-radiotherapy for the treatment of advanced middle to lower rectal cancers.

Authors:  K Koda; N Saito; K Oda; N Takiguchi; H Sarashina; M Miyazaki
Journal:  Int J Colorectal Dis       Date:  2003-11-22       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.